Trial reportPLoS neglected tropical diseases2013
Corticosteroids for dengue - why don't they work?
Trial report in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Corticosteroids for dengue infection.The Cochrane database of systematic reviews · 2014Pooled it
- Dengue Virus Infection: Immune Response and Therapeutic Targets.The American journal of tropical medicine and hygiene · 2025Review
- Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19.Frontiers in immunology · 2022Review
- IL-18: The Forgotten Cytokine in Dengue Immunopathogenesis.Journal of immunology research · 2021Review
- Similarities and differences between the 'cytokine storms' in acute dengue and COVID-19.Scientific reports · 2020Article
- Review
- Recent advances in understanding dengue.F1000Research · 2019Review
- Article
- Review
- Host-directed therapies for bacterial and viral infections.Nature reviews. Drug discovery · 2018Review
- Genomic approaches for understanding dengue: insights from the virus, vector, and host.Genome biology · 2016Review
- Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.PLoS neglected tropical diseases · 2014Review
- Cardiovascular manifestations of the emerging dengue pandemic.Nature reviews. Cardiology · 2014Review
- Corticosteroids in the treatment of dengue shock syndrome.Infection and drug resistance · 2014Review
- Acute kidney injury associated with dengue virus infection: a review.Jornal brasileiro de nefrologiaReview
- Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment.Current treatment options in infectious diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 6 countries.
Funding
Abstract
backgroundDysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue.
findingsIn Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels.
conclusionThe inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.